Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 217

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Screening for Hepatocellular Carcinoma in Chronic Liver Disease: A Systematic Review

Kansagara, Devan, Papak, Joel, Pasha, Amirala S., O’Neil, Maya, Freeman, Michele, Relevo, Rose, Quiñones, Ana, Motu’apuaka, Makalapua, Jou, Janice H.·2014·Annals of Internal Medicine

Abstract

BACKGROUND: Guidelines recommend routine screening for hepatocellular carcinoma (HCC) in high-risk patients, but the strength of evidence supporting these recommendations is unclear. PURPOSE: To review the benefits and harms of HCC screening in patients with chronic liver disease. DATA SOURCES: MEDLINE, PsycINFO, and ClinicalTrials.gov from inception to April 2014; Cochrane databases to June 2013; reference lists; and technical advisors. STUDY SELECTION: English-language trials and observational studies comparing screening versus no screening, studies of harms, and trials comparing different screening intervals. DATA EXTRACTION: Mortality and adverse events were the outcomes of interest. Individual-study quality and the overall strength of evidence were dual-reviewed using published criteria. DATA SYNTHESIS: Of 13,801 citations, 22 studies met inclusion criteria. The overall strength of evidence on the effects of screening was very low. One large trial of patients with hepatitis B found decreased HCC mortality with periodic ultrasonographic screening (rate ratio, 0.63 [95% CI, 0.41 to 0.98]), but the study was limited by methodological flaws. Another trial in patients with hepatitis B found no survival benefit with periodic α-fetoprotein screening. In 18 observational studies, screened patients had earlier-stage HCC than clinically diagnosed patients, but lead- and length-time biases confounded the effects on mortality. Two trials found no survival differences between shorter (3- to 4-month) and longer (6- to 12-month) screening intervals. Harms of screening were not well-studied. LIMITATIONS: Only English-language studies were included. The evidence base is limited by methodological issues and a paucity of trials. CONCLUSION: There is very-low-strength evidence about the effects of HCC screening on mortality in patients with chronic liver disease. Screening tests can identify early-stage HCC, but whether systematic screening leads to a survival advantage over clinical diagnosis is uncertain. PRIMARY FUNDING SOURCE: U.S. Department of Veterans Affairs Quality Enhancement Research Initiative.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/m14-0558

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 217

Metadata

Authors
Kansagara, D., Papak, J., Pasha, A. S., O’Neil, M., Freeman, M., Relevo, R., Quiñones, A., Motu’apuaka, M., & Jou, J. H.
Venue
Annals of Internal Medicine
Published
2014-08-19
Volume
161
Issue
4
Pages
261-269
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W1964070738
Cited by
217
References
4
FWCI
12.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Screening for Hepatocellular Carcinoma in Chronic Liver Disease: A Systematic Review. https://app.cochat.ai/papers/10.7326/m14-0558
The paper
Kansagara, D., Papak, J., Pasha, A. S., O’Neil, M., Freeman, M., Relevo, R., Quiñones, A., Motu’apuaka, M., & Jou, J. H. (2014). Screening for Hepatocellular Carcinoma in Chronic Liver Disease: A Systematic Review. Annals of Internal Medicine. https://doi.org/10.7326/m14-0558

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.